SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2013 Financial Results
[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []
